Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
CAMBRIDGE, Mass., April 23, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, will report first quarter 2018 financial results after the Nasdaq Global Market closes on Thursday, May 3, 2018. Subsequently, at 4:30 p.m. Eastern Time, the Company will host a conference call to discuss its first quarter 2018 financial results and to provide a corporate update.
The conference call may be accessed by dialing 844-534-7313 for domestic callers and +1-574-990-1451 for international callers. The passcode for the call is 2798939. Please specify to the operator that you would like to join the "Sarepta First Quarter 2018 Earnings Call". The conference call will be webcast live under the investor relations section of Sarepta's website at www.sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]
